[HTML][HTML] A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
T Noy-Porat, E Makdasi, R Alcalay, A Mechaly… - Nature …, 2020 - nature.com
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
[HTML][HTML] Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Understanding the mechanism for antibody neutralization of SARS-CoV-2 is critical for the
development of effective therapeutics and vaccines. We recently isolated a large number of …
development of effective therapeutics and vaccines. We recently isolated a large number of …
[HTML][HTML] Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
MF Jennewein, AJ MacCamy, NR Akins, J Feng… - Cell reports, 2021 - cell.com
SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier
and caused widespread disease in the past two decades. The development of a universal …
and caused widespread disease in the past two decades. The development of a universal …
[HTML][HTML] A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
C Kim, DK Ryu, J Lee, YI Kim, JM Seo, YG Kim… - Nature …, 2021 - nature.com
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
[HTML][HTML] Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
Immediately from the outset of the COVID-19 pandemic, researchers from diverse
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …
[HTML][HTML] An engineered bispecific human monoclonal antibody against SARS-CoV-2
Z Li, S Li, G Zhang, W Peng, Z Chang, X Zhang… - Nature …, 2022 - nature.com
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
[HTML][HTML] Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
SARS-CoV-2 is a betacoronavirus virus responsible for the COVID-19 pandemic. Here, we
determine the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30 …
determine the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30 …
[HTML][HTML] Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation
Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …
[HTML][HTML] Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …
[HTML][HTML] SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …